Bavarian Nordic A/S - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Bavarian Nordic A/S - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Bavarian Nordic A/S - Product Pipeline Review - 2014', provides an overview of the Bavarian Nordic A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bavarian Nordic A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Bavarian Nordic A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Bavarian Nordic A/S's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Bavarian Nordic A/S's pipeline products

Reasons to buy

- Evaluate Bavarian Nordic A/S's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Bavarian Nordic A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Bavarian Nordic A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Bavarian Nordic A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bavarian Nordic A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Bavarian Nordic A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Bavarian Nordic A/S Snapshot 5
Bavarian Nordic A/S Overview 5
Key Information 5
Key Facts 5
Bavarian Nordic A/S - Research and Development Overview 6
Key Therapeutic Areas 6
Bavarian Nordic A/S - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Bavarian Nordic A/S - Pipeline Products Glance 11
Bavarian Nordic A/S - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Bavarian Nordic A/S - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Bavarian Nordic A/S - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Bavarian Nordic A/S - Drug Profiles 16
Live Modified Vaccinia Virus Ankara 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
rilimogene galvacirepvec 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CV-301 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
MVA-BN-HER2 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
MVA-BN-PRO 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
MVA-BN Anthrax 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
MVA-BN-Brachyury 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
MVA-BN-Filoviruses Vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MVA-BN-RSV 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Vaccine for Burkholderia Infections 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Bavarian Nordic A/S - Pipeline Analysis 29
Bavarian Nordic A/S - Pipeline Products by Target 29
Bavarian Nordic A/S - Pipeline Products by Route of Administration 31
Bavarian Nordic A/S - Pipeline Products by Molecule Type 32
Bavarian Nordic A/S - Recent Pipeline Updates 33
Bavarian Nordic A/S - Dormant Projects 39
Bavarian Nordic A/S - Discontinued Pipeline Products 40
Discontinued Pipeline Product Profiles 40
MVA-BN Dengue Fever Vaccine 40
MVA-BN-JEV 40
Bavarian Nordic A/S - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Bavarian Nordic A/S, Key Information 5
Bavarian Nordic A/S, Key Facts 5
Bavarian Nordic A/S - Pipeline by Indication, 2014 8
Bavarian Nordic A/S - Pipeline by Stage of Development, 2014 9
Bavarian Nordic A/S - Monotherapy Products in Pipeline, 2014 10
Bavarian Nordic A/S - Phase III, 2014 11
Bavarian Nordic A/S - Phase II, 2014 12
Bavarian Nordic A/S - Phase I, 2014 13
Bavarian Nordic A/S - Preclinical, 2014 14
Bavarian Nordic A/S - Discovery, 2014 15
Bavarian Nordic A/S - Pipeline by Target, 2014 30
Bavarian Nordic A/S - Pipeline by Route of Administration, 2014 31
Bavarian Nordic A/S - Pipeline by Molecule Type, 2014 32
Bavarian Nordic A/S - Recent Pipeline Updates, 2014 33
Bavarian Nordic A/S - Dormant Developmental Projects,2014 39
Bavarian Nordic A/S - Discontinued Pipeline Products, 2014 40
Bavarian Nordic A/S, Other Locations 41
Bavarian Nordic A/S, Subsidiaries 41